Antimicrobial resistance in gonorrhoea: Rising threat to treatment efficacy

The European Union/European Economic Area (EU/EEA) has reported a 48% increase in confirmed cases of gonorrhoea in 2022, with two isolates resistant to ceftriaxone, the recommended antibiotic for treating the disease. The rise in resistance to azithromycin and ciprofloxacin is concerning, as they are often used alongside ceftriaxone. The ECDC recommends enhanced surveillance, quality-assured antimicrobial susceptibility surveillance, and regular review of treatment guidelines. Investing in developing new antimicrobial treatments and alternative regimens is also crucial. Strengthening public health initiatives, including increased access to diagnostic services, and fostering international cooperation are also recommended. Prevention, including safe sexual practices, testing for sexually transmitted infections, and prudent use of antimicrobials, is also crucial to curb the spread of gonorrhoea.